CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
功能核酸增强 CAR-T 细胞治疗
英文原题：Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.
查看英文原题
Enhancing CAR-T Cell Therapy with Functional Nucleic Acids.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法是一种相对较新的免疫治疗形式，在治疗血液系统恶性肿瘤患者方面取得了成功，促使美国食品药品监督管理局近期批准了三项疗法。然而，若干挑战阻碍了CAR-T 疗法的广泛应用。在此，我们综述了适体和核酶等功能性核酸作为新型工具的应用，以改进CAR-T 细胞疗法开发中的多个步骤。我们批判性地审视了突出功能性核酸在细胞疗法不同阶段优势的关键研究，并讨论了其实际临床应用的可行性。最后，我们展望了潜在机遇，即化学家可以在创新性地整合功能性核酸以克服这一前沿免疫治疗相关挑战方面做出重要贡献。
展开英文摘要原文
Chimeric antigen receptor (CAR) T cell therapy is a relatively new form of immunotherapy that has had success in treating patients with hematologic malignancies, leading to three recent United States Food and Drug Administration approvals.
However, several challenges hinder the widespread use of CAR-T therapy.
Here, we review the application of functional nucleic acids such as aptamers and ribozymes as novel tools to improve a variety of steps in CAR-T cell therapy development.
We critically examine key studies that highlight the benefits of functional nucleic acids at different stages of cell-based therapy and discuss the feasibility of their practical clinical application.
Finally, we offer insights into potential opportunities where chemists can significantly contribute to the innovative incorporation of functional nucleic acids to overcome challenges associated with this cutting-edge immunotherapy.
论文信息
- 作者
- Maru B、Nadeau L、McKeague M
- 单位
- Pharmacology and Therapeutics, Faculty of Medicine, McGill University, 3655 Promenade Sir William Osler, Montreal, QC H3G 1Y6, Canada.Italy
- 文献类型
- 综述
- 期刊
- ACS pharmacology & translational science2021 Dec 10
- 原文标识
- PubMed 34927006 · DOI 10.1021/acsptsci.1c00188
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →